MPPE1 and neoplasm: As DCs, especially cDC1, tend to correlate with a positive prognosis when they are present in tumors, therapies targeting DCs focus on enhancing DC function, increasing their numbers, or bypassing the tumor microenvironment to promote systemic de novo anti-tumor immunity (Figure 2).